z-logo
Premium
Fine‐Needle Aspiration Cytology of Renal‐Cell Adenocarcinoma Metastatic to the Breast: A Report of Three Cases
Author(s) -
Chhieng David C.,
Cohen JeanMarc,
Waisman Jerry,
Fernandez Gerry,
Skoog Lambert,
Cangiarella Joan F.
Publication year - 1999
Publication title -
diagnostic cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 65
eISSN - 1097-0339
pISSN - 8755-1039
DOI - 10.1002/(sici)1097-0339(199911)21:5<324::aid-dc5>3.0.co;2-q
Subject(s) - medicine , fine needle aspiration , adenocarcinoma , pathology , biopsy , renal cell carcinoma , cytology , metastasis , cytopathology , clear cell carcinoma , radiology , carcinoma , cancer
Metastases to the breast from extramammary primary malignancies, including renal adenocarcinoma, are rare. Fine‐needle aspiration biopsy (FNA) is a useful, noninvasive, and rapid procedure to evaluate these mammary lesions. This study describes the cytomorphology of 3 cases of renal‐cell adenocarcinoma metastatic to the breast. All patients had a prior history of renal‐cell adenocarcinoma treated with radical nephrectomy, and they presented with a solitary mammary mass. The cytologic findings showed irregular clusters and dispersed single cells with eccentric nuclei and abundant, vacuolated cytoplasm in a hemorrhagic background. The nuclei were round to oval, with fine granular chromatin and a single, prominent nucleolus. All aspirates were interpreted initially and correctly as consistent with metastatic renal‐cell adenocarcinoma. In summary, a cytologic diagnosis of renal‐cell adenocarcinoma metastatic to the breast can be made by correlating clinical and cytologic findings. The distinction between metastatic extramammary malignancies to the breast and primary mammary carcinoma is critical to avoid unnecessary surgery and to ensure appropriate chemotherapy or radiation therapy. Diagn. Cytopathol. 21:324–327, 1999. © 1999 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here